Enabling Access to MDR-TB Medicine through the Stop TB Partnership Global Drug Facility (GDF)
Since 2014, Johnson & Johnson has made its medicine for multidrug-resistant tuberculosis (MDR-TB) accessible to more than 135 low- and middle-income countries procuring through the Stop TB Partnership’s Global Drug Facility (GDF).
Johnson & Johnson and the Global Drug Facility are working to maximize access to the Company’s MDR-TB medicine in support of the World Health Organization’s guidelines for the treatment of drug-resistant TB (DR-TB).
What are the health needs and challenges?
Tuberculosis (TB) is one of the world’s deadliest infectious diseases, claiming 1.6 million lives every year. Approximately 95 percent of these deaths occur in low- and middle-income countries. Growing resistance to the most commonly-used TB medicines is compounding this challenge. In fact, there are more than half a million cases of drug-resistant tuberculosis (DR-TB) every year, and DR-TB now accounts for nearly one-third of all deaths directly attributable to antimicrobial resistance (AMR).
Activities and how they address needs and challenges
In late 2012, Johnson & Johnson introduced its medicine for the treatment of pulmonary multidrug-resistant TB (MDR-TB) – and the first novel TB medicine to be approved in more than 40 years.
Since 2014, Johnson & Johnson has worked with the Stop TB Partnership’s Global Drug Facility (GDF) to deliver our MDR-TB medicine to those in need, including through a four-year donation program from 2015-2019 in collaboration with USAID and JSC Pharmstandard. Today, our medicine is available to more than 135 low- and middle-income countries procuring through the GDF, a model which was recognized by the Access to Medicine Foundation in 2021 as a “best practice.”
“As part of our decades-long commitment in the fight against TB, Johnson & Johnson has worked to deploy innovative approaches to expand access to our multidrug-resistance TB medicine in low- and middle-income countries, delivering more than 600,000 courses of medicine to 158 countries.”
- Global Commitment
- Infectious and Parasitic Disease
SGDs the partnership contributes to
- 3.3: Communicable diseases and NTDs
- 3.8: Achieve universal health coverage
Infectious and Parasitic Disease
- Drug-Resistant Infections (AMR)